Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14416063 | 0.88 | FNTA (0.40) | FNTAFNTB | |
| SCHEMBL13935172 | 0.88 | FNTA (0.40) | FNTAFNTB | |
| SCHEMBL13611672 | 0.84 | FNTA (0.50) | FNTAFNTB | |
| SCHEMBL13604621 | 0.84 | FNTA (0.51) | FNTAFNTB | |
| SCHEMBL14416132 | 0.84 | FNTA (0.36) | FNTAFNTB | |
| SCHEMBL14416121 | 0.83 | FNTA (0.38) | FNTAFNTB | |
| SCHEMBL13604328 | 0.81 | FNTA (0.50) | FNTAFNTB | |
| SCHEMBL13935192 | 0.80 | FNTA (0.37) | FNTAFNTB | |
| SCHEMBL13935158 | 0.80 | FNTA (0.49) | FNTAFNTB | |
| SCHEMBL14082748 | 0.78 | FNTA (0.36) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7485645-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485645-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1572299-B1 | 17 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080004248-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004248-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-7271175-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271175-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140902-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-1140904-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037459-A1 | TRICYCLIC FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| US-5965570-A | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE ABNORMAL GROWTH OF CELLS; ADMINISTERING TO INHIBIT TUMOR CELLS WHEREIN THE RAS PROTEIN IS ACTIVATED AS A RESULT OF ONCOGENIC MUTATION IN GENES OTHER THAN THE RAS GENE | SCHERING CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0931077-A1 | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0931078-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998011098-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998011097-A1 | SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | FNTA 2/4885FNTB 1/4885 |
| US-20080004248-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | HSD17B3, HSD17B1, HSD17B11 | FNTA 1025/4885FNTB 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.